General discussion, page-1117

OSA Phase 2B Human Trial (Camargo identified as FDA Accelerated Pathway Candidate)
- https://www.asx.com.au/asxpdf/20200709/pdf/44kcy0slwc7xq2.pdf (Latest Update w/ Alfred Hospital)
- https://www.asx.com.au/asxpdf/20200325/pdf/44gcpycyqvdmz0.pdf
TBI Human Trial (Camargo identified as FDA Accelerated Pathway Candidate)
- https://www.asx.com.au/asxpdf/20200423/pdf/44h5xbzd332khz.pdf

ARDS Animal Trial
- https://www.asx.com.au/asxpdf/20200415/pdf/44gyql9zyjtwms.pdf (Original Announcement)
- https://www.asx.com.au/asxpdf/20200602/pdf/44j9s243x5b3cl.pdf (Commencement of Study)

TMJ (No News on this one)

I think with OSA and TBI because of the existing amount of work available for both areas and the formulations that IHL is coming up with we can go straight to human trials. Because of this, IHL has filed patents and got consulted Camargo as to the likelihood of the FDA granting them with an accelerated pathway subject to clinical trial success. With ARDS, I think it's new and revolutionary even moreso than the others so they are starting with animal trials first.

I think once animal trials are proven to be successful then IHL will proceed to a human trial and then file patents, consult Camargo again or straight up meet with the FDA directly if the Animal Trials count as "clinical success".

@Leigh1983 Hope this answers your question too.